Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson has completed its previously announced acquisition of Omrix Biopharmaceuticals, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
Subscribe to our email newsletter
Omrix is expected to operate as a stand-alone entity reporting through Ethicon, a Johnson & Johnson company.